Evidence map›Paper›PMID 40611893›Full record

ArticlebioRxiv : the preprint server for biology2025

Fibulin-4 is highly expressed in metastatic breast cancer and can serve as a target of peptide-based imaging probes and experimental therapeutics.

Alexes C Daquinag, Solmaz AghaAmiri, Stephen M Farmer, Sheng Zhang, Sukhen C Ghosh, Servando Hernandez Vargas, Ashwin K Ramesh, Zhiqiang An, Ali Azhdarinia, Mikhail G Kolonin

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Alexes C DaquinagCenter for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Solmaz AghaAmiriCenter for Translational Cancer Research, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Stephen M FarmerCenter for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Sheng ZhangCenter for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Sukhen C GhoshCenter for Translational Cancer Research, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Servando Hernandez VargasCenter for Translational Cancer Research, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Ashwin K RameshTexas Therapeutics Institute, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Zhiqiang AnTexas Therapeutics Institute, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Ali AzhdariniaCenter for Translational Cancer Research, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.
Mikhail G KoloninCenter for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, The University of Texas MD Anderson Cancer Center and UTHealth, Houston, Texas 77030.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously reported a cyclic peptide CRAGVGRGC (termed BLMP6) that homes to disseminating tumor cells in mouse cancer models and could be used for metastasis detection and intervention. Here, based on BLMP6 similarity to latent transforming growth factor beta binding protein 4 (LTBP4), we discovered fibulin-4 as a BLMP6 target. We show that BLMP6 mimics the LTBP4 domain binding to fibulin-4 and selectively binds to fibulin-4 in vitro. Fibulin-4 knockout in mouse 4T1 cancer cells abrogated BLMP6 homing to lung metastases. Fibulin-4 expression was found to be increased in invasive and metastatic human breast cancer. AZDye555 fluorophore-labeled BLMP6 was developed as a reagent selectively binding to invasive and metastatic human breast cancer cells in tissue sections and homing to MDA-MB-231 metastases in mice. We show that radiolabeling BLMP6 with

Indexed as

breastCancerfibulin-4LTBP4metastasisMMAEpeptide-drug conjugate

Identifiers

PMID40611893
PMCPMC12224531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.